UBS Group’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$404K Buy
31,981
+12,945
+68% +$148K ﹤0.01% 6230
2025
Q4
$196K Buy
19,036
+126
+0.7% +$1.06K ﹤0.01% 6589
2025
Q3
$110K Sell
18,910
-5,849
-24% -$34.2K ﹤0.01% 7053
2025
Q2
$166K Sell
24,759
-26,280
-51% -$211K ﹤0.01% 6841
2025
Q1
$461K Sell
51,039
-2,052
-4% -$25.6K ﹤0.01% 5912
2024
Q4
$918K Buy
53,091
+28,100
+112% +$509K ﹤0.01% 5373
2024
Q3
$399K Buy
24,991
+3,176
+15% +$50K ﹤0.01% 5387
2024
Q2
$311K Sell
21,815
-1,654
-7% -$23.5K ﹤0.01% 5370
2024
Q1
$333K Buy
23,469
+993
+4% +$14K ﹤0.01% 5501
2023
Q4
$339K Buy
22,476
+9,165
+69% +$136K ﹤0.01% 5412
2023
Q3
$210K Sell
13,311
-377
-3% -$5.94K ﹤0.01% 5335
2023
Q2
$207K Buy
13,688
+12,231
+839% +$169K ﹤0.01% 5454
2023
Q1
$21.1K Buy
1,457
+200
+16% +$2.67K ﹤0.01% 7037
2022
Q4
$17K Buy
+1,257
New +$22K ﹤0.01% 7864
2022
Q3
Sell
-597
Closed -$8K 10934
2022
Q2
$8K Sell
597
-850
-59% -$6.45K ﹤0.01% 8353
2022
Q1
$13K Sell
1,447
-1,367
-49% -$14.7K ﹤0.01% 8082
2021
Q4
$48K Buy
+2,814
New +$68.2K ﹤0.01% 6942

Other funds holding TRDA